📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

JAK inhibition by methotrexate (and csDMARDs) may explain clinical efficacy as monotherapy and combination therapy. (2019)

First Author: Gremese E

Attributed to: Addressing the funding gap to advance early stage healthcare research at the University of Sheffield funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/jlb.5ru0519-145r

PubMed Identifier: 31313387

Publication URI: http://europepmc.org/abstract/MED/31313387

Type: Journal Article/Review

Volume: 106

Parent Publication: Journal of leukocyte biology

Issue: 5

ISSN: 0741-5400